The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009

Xiaoxin Zhang, Qiaoqiao Xu, Lirun Yang, Yueyang Lai, Zhuangzhuang Zhang, Chao Han, Chizhou Jiang, Jiahuang Li, Yixin Shi, Zi Chun Hua

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

VNP20009 is a very effective anti-cancer agent and can specifically target tumors and inhibit tumor growth. It was assumed that the tumor targeting ability of VNP20009 correlated to its anticancer capacity. However, our observation contradicted to this assumption. Three VNP20009 mutant strains (ΔslyA, ΔSTM3120 and ΔhtrA) with reduced fitness in normal tissues and unchanged fitness in tumors partially or completely lost their anti-cancer capacities. The genes slyA, STM3120 and htrA were required for survival within macrophages and were indispensable for tumor microenvironment remodeling by VNP20009. The infiltration of immune cells occurred less in the tumors of mice infected with the mutant strains. In addition, the mRNA levels of TNF-α and IL-1β were significantly decreased in the tumors of mice treated with the mutant strains. Our results indicate that the immune responses elicited by bacteria rather than the bacterial titer in tumors play a "decisive" role in VNP20009-mediated bacterial cancer therapy, which provides a novel perspective for the underlying mechanism of bacterial cancer therapy.

Original languageEnglish (US)
Pages (from-to)81187-81196
Number of pages10
JournalOncotarget
Volume7
Issue number49
DOIs
StatePublished - 2016

Fingerprint

Genes
Neoplasms
VNP 20009
Tumor Microenvironment
Interleukin-1
Macrophages
Observation
Bacteria
Messenger RNA
Therapeutics
Growth

Keywords

  • Bacteria
  • Cancer
  • Immune response
  • Tumor-targeting
  • VNP20009

ASJC Scopus subject areas

  • Oncology

Cite this

Zhang, X., Xu, Q., Yang, L., Lai, Y., Zhang, Z., Han, C., ... Hua, Z. C. (2016). The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009. Oncotarget, 7(49), 81187-81196. https://doi.org/10.18632/oncotarget.13217

The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009. / Zhang, Xiaoxin; Xu, Qiaoqiao; Yang, Lirun; Lai, Yueyang; Zhang, Zhuangzhuang; Han, Chao; Jiang, Chizhou; Li, Jiahuang; Shi, Yixin; Hua, Zi Chun.

In: Oncotarget, Vol. 7, No. 49, 2016, p. 81187-81196.

Research output: Contribution to journalArticle

Zhang, X, Xu, Q, Yang, L, Lai, Y, Zhang, Z, Han, C, Jiang, C, Li, J, Shi, Y & Hua, ZC 2016, 'The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009', Oncotarget, vol. 7, no. 49, pp. 81187-81196. https://doi.org/10.18632/oncotarget.13217
Zhang, Xiaoxin ; Xu, Qiaoqiao ; Yang, Lirun ; Lai, Yueyang ; Zhang, Zhuangzhuang ; Han, Chao ; Jiang, Chizhou ; Li, Jiahuang ; Shi, Yixin ; Hua, Zi Chun. / The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009. In: Oncotarget. 2016 ; Vol. 7, No. 49. pp. 81187-81196.
@article{ae628f69b01a423289850a30c6dc57b5,
title = "The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009",
abstract = "VNP20009 is a very effective anti-cancer agent and can specifically target tumors and inhibit tumor growth. It was assumed that the tumor targeting ability of VNP20009 correlated to its anticancer capacity. However, our observation contradicted to this assumption. Three VNP20009 mutant strains (ΔslyA, ΔSTM3120 and ΔhtrA) with reduced fitness in normal tissues and unchanged fitness in tumors partially or completely lost their anti-cancer capacities. The genes slyA, STM3120 and htrA were required for survival within macrophages and were indispensable for tumor microenvironment remodeling by VNP20009. The infiltration of immune cells occurred less in the tumors of mice infected with the mutant strains. In addition, the mRNA levels of TNF-α and IL-1β were significantly decreased in the tumors of mice treated with the mutant strains. Our results indicate that the immune responses elicited by bacteria rather than the bacterial titer in tumors play a {"}decisive{"} role in VNP20009-mediated bacterial cancer therapy, which provides a novel perspective for the underlying mechanism of bacterial cancer therapy.",
keywords = "Bacteria, Cancer, Immune response, Tumor-targeting, VNP20009",
author = "Xiaoxin Zhang and Qiaoqiao Xu and Lirun Yang and Yueyang Lai and Zhuangzhuang Zhang and Chao Han and Chizhou Jiang and Jiahuang Li and Yixin Shi and Hua, {Zi Chun}",
year = "2016",
doi = "10.18632/oncotarget.13217",
language = "English (US)",
volume = "7",
pages = "81187--81196",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "49",

}

TY - JOUR

T1 - The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009

AU - Zhang, Xiaoxin

AU - Xu, Qiaoqiao

AU - Yang, Lirun

AU - Lai, Yueyang

AU - Zhang, Zhuangzhuang

AU - Han, Chao

AU - Jiang, Chizhou

AU - Li, Jiahuang

AU - Shi, Yixin

AU - Hua, Zi Chun

PY - 2016

Y1 - 2016

N2 - VNP20009 is a very effective anti-cancer agent and can specifically target tumors and inhibit tumor growth. It was assumed that the tumor targeting ability of VNP20009 correlated to its anticancer capacity. However, our observation contradicted to this assumption. Three VNP20009 mutant strains (ΔslyA, ΔSTM3120 and ΔhtrA) with reduced fitness in normal tissues and unchanged fitness in tumors partially or completely lost their anti-cancer capacities. The genes slyA, STM3120 and htrA were required for survival within macrophages and were indispensable for tumor microenvironment remodeling by VNP20009. The infiltration of immune cells occurred less in the tumors of mice infected with the mutant strains. In addition, the mRNA levels of TNF-α and IL-1β were significantly decreased in the tumors of mice treated with the mutant strains. Our results indicate that the immune responses elicited by bacteria rather than the bacterial titer in tumors play a "decisive" role in VNP20009-mediated bacterial cancer therapy, which provides a novel perspective for the underlying mechanism of bacterial cancer therapy.

AB - VNP20009 is a very effective anti-cancer agent and can specifically target tumors and inhibit tumor growth. It was assumed that the tumor targeting ability of VNP20009 correlated to its anticancer capacity. However, our observation contradicted to this assumption. Three VNP20009 mutant strains (ΔslyA, ΔSTM3120 and ΔhtrA) with reduced fitness in normal tissues and unchanged fitness in tumors partially or completely lost their anti-cancer capacities. The genes slyA, STM3120 and htrA were required for survival within macrophages and were indispensable for tumor microenvironment remodeling by VNP20009. The infiltration of immune cells occurred less in the tumors of mice infected with the mutant strains. In addition, the mRNA levels of TNF-α and IL-1β were significantly decreased in the tumors of mice treated with the mutant strains. Our results indicate that the immune responses elicited by bacteria rather than the bacterial titer in tumors play a "decisive" role in VNP20009-mediated bacterial cancer therapy, which provides a novel perspective for the underlying mechanism of bacterial cancer therapy.

KW - Bacteria

KW - Cancer

KW - Immune response

KW - Tumor-targeting

KW - VNP20009

UR - http://www.scopus.com/inward/record.url?scp=85000885460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000885460&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13217

DO - 10.18632/oncotarget.13217

M3 - Article

C2 - 27835896

AN - SCOPUS:85000885460

VL - 7

SP - 81187

EP - 81196

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 49

ER -